First up this week is a trial team at Quinn Emanuel Urquhart & Sullivan led by Bill Price, Steig Olson and Rachael McCracken that secured a nine-digit antitrust verdict for client Pacific Steel Group in litigation against Commercial Metals Company. Federal jurors in Oakland, California this week found that CMC suppressed competition in the market for rebar by pushing micromill-maker Danieli Corp. into a three-year exclusivity contract barring it from developing mills located within 500 miles of Rancho Cucamonga, California, leading to delays and extra costs for PSG's expansion into the market. Jurors awarded PSG $110 million, the full amount of requested damages and a number that's subject to trebling. The trial team for PSG also included Dan McCuaig and Ben Brown of Cohen Milstein Sellers & Toll.

 A Latham & Watkins team led by partners Phil Perry, Andrew Prins and counsel Nick Schlossman secured a win for Avadel CNS Pharmaceuticals allowing it to continue marketing and selling its narcolepsy drug Lumryz, which has a once-nightly dosing regimen. Jazz Pharmaceuticals, the maker of twice-nightly narcolepsy drugs, sued the Food and Drug Administration in 2023, challenging the approval of Lumryz, and Avadel, represented by Latham, intervened. U.S. District Judge Amit Mehta in Washington, D.C. last week granted summary judgment to Avadel, finding that the FDA had reasonably concluded "once-nightly dosing offers a better chance at achieving less disrupted sleep" and that the agency's approval of Lumryz was not arbitrary or capricious. Perry argued the summary judgment motion for Avadel. The team also included partner John Manthei and counsel Amy Speros and associates Richard Frohlichstein, William Seidleck, Kimon Triantafyllou, Alex Siemers, Joseph Sitzmann, Alon Handler and Lia Barrett.